Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice.
Frustaci AM, Galitzia A, Lucignano M, Appio L, Olivieri J, Sanna A, Baraté C, Pane F, Schiattone L, Casadei B, Ferrarini I, Figuera A, Sportoletti P, Loseto G, Stelitano C, Visentin A, Celli M, Mauro FR, Palombi M, Coscia M, Innao V, Moia R, Motta M, Russo F, Tani M, Arcari A, Boccellato E, Borella C, Capochiani E, Ferrari A, Gentile M, Giachetti R, Giordano A, Bullo M, Lista E, Malandruccolo L, Musso M, Varettoni M, Vozella F, Cibien F, Merli M, Nocilli L, Pasquini MC, Romeo AA, Rossi V, Turri G, Vanazzi A, Cavaliere M, Gozzetti A, Crucitti L, Lucesole M, Deodato M, Tomasso A, Zappaterra A, Murru R, Patti C, Laurenti L, Tedeschi A.
Frustaci AM, et al. Among authors: mauro fr.
Haematologica. 2025 Jun 26. doi: 10.3324/haematol.2025.287799. Online ahead of print.
Haematologica. 2025.
PMID: 40568727
Free article.